These results confirm a tumor suppressor role for GPS2 in breast cancer, in agreement with in silico analysis of the distribution of GPS2 expression across human tumor types, using data from the TCGA PanCancer Studies on cBioPortal, showing a trend toward low GPS2 expression, associated with deletions and truncating events, in invasive breast cancer samples (Supplementary Figure 2C). Here, GPS2 is linked to breast carcinoma.